DCB-DM101 in Healthy Volunteers and for Type 2 Diabetes Mellitus Patients
Status:
Completed
Trial end date:
2018-08-01
Target enrollment:
Participant gender:
Summary
An Open-Label Phase I Study to Assess the Safety and Tolerability Profile of Three Escalating
Doses of DCB-DM101 in Healthy Volunteers and Optimum Dose of DCB-DM101 as Add-on Treatment in
Type 2 Diabetes Mellitus (T2DM) Patients